Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with paroxysmal or persistent AF eligible for catheter ablation
- Age 18 to 80 years
- Able and willing to comply with all pre,post and follow-up testing and requirements.
- Be able to sign IRB/EC approved informed consent form.
Exclusion Criteria:
- Terminal illness with a life expectancy less than 1 year.
- New York Heart Association (NYHA) Class III or IV
- Previous recipient of catheter ablation therapy for AF
- Bradycardia and previous recipient of pacemaker therapy
- Previous recipient RFCA or ICD therapy
- Uncontrolled hypertension
- Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months
- Patients with serious hepatic and renal diseases
- Pregnant or prepare to be pregnant in one year
- For drug therapy arm, if the subject cannot be contacted via phone or the subject shows his/her disagreement to this study at 30 day window, the subject will be withdrawn from this study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the frequency of recurrence
Time Frame: 9 months followup after baseline
|
the frequency of recurrence of Atrial Fibrillation/Flutter/Tachycardia
|
9 months followup after baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate
Time Frame: 9 month follow up after baseline
|
Total mortality
|
9 month follow up after baseline
|
|
total cost
Time Frame: 9 months follow up
|
Average total costs of ablation vs. drug therapy per patient
|
9 months follow up
|
|
Rate
Time Frame: 9 months follow up from baseline
|
Stroke
|
9 months follow up from baseline
|
|
Rate
Time Frame: 9 months from baseline
|
Cardiovascular death/Arrhythmic death or Cardiac arrest/Heart failure death
|
9 months from baseline
|
|
Duration
Time Frame: 9 months from baseline
|
Cardiovascular or Cerebrovascular hospitalization
|
9 months from baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAAF 2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.